Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (“Biophytis”), an innovative clinical-stage biotechnology firm dedicated to developing therapeutics to retard degenerative processes associated with aging, and SEQENS, a comprehensive global provider of solutions and substances for the pharmaceutical and specialty sectors, have formed a master agreement for the manufacture of precise active compound in Sarconeos (BIO101).
The drug will be utilized to address severe forms of Covid-19, sarcopenia, and Duchenne muscular dystrophy. This breakthrough advancement marks the beginning of potential new treatments to address these critical and widespread illnesses.
SEQENS, producing the active ingredient in Sarconeos (BIO101), has opened a cutting-edge production center at its Villeneuve La Garenne plant near Paris. This remarkable facility has been upgraded and upgraded in 2020, allowing it to generate high-potential active pharmaceutical ingredients (APIs). All of this is in accordance with SEQENS’ efforts to create a safe and sustainable environment for its workers and reduce its carbon footprint.
Stanislas Veillet, Chairman and CEO of Biophytis, is thrilled to announce a new and important partnership with SEQENS. This opportunity provides Biophytis with secure production of the active ingredient in their main drug candidate, Sarconeos (BIO101).
This critical progress in support of Biophytis’ commitment to providing early access programs and filing market access applications for Sarconeos in the treatment of severe forms of Covid-19 is made possible due to SEQENS’ expertise and compliance with manufacturing standards.
We are excited to be able to harness our expertise and bring it into this new partnership with Biophytis, in the hopes of improving the quality of life for millions around the world. This expedited collaboration is key for national and European health sovereignty, and now more than ever illustrates our ongoing determination to produce new molecules with the potential of offering France unparalleled advantages. SEQENS is proud to be part of this journey.
BioPhytis SA, a pioneering clinical-stage biotech company, is on a mission to bring relief to people suffering from age-related diseases. Their lead drug candidate, Sarconeos (BIO101), is a small molecule being developed to treat neuromuscular (sarcopenia and Duchene’s muscular dystrophy) and cardiorespiratory (Covid-19) diseases.
The drug has achieved promising clinical results in the treatment of sarcopenia in phase 2 trials, and is now being prepared for a phase 3 trial (SARA project). Additionally, a phase 2-3 clinical trial conducted to test the safety and efficacy of Sarconeos (BIO101) for severe Covid-19 patients has yielded positive results, allowing for the preparation of conditional marketing authorization (CMA) applications in Europe and Emergency Use Authorization (EUA) applications in the US.
Furthermore, the company is also working to develop a pediatric formulation of Sarconeos (BIO101) for treating Duchenne Muscular Dystrophy (DMD, MYODA project). Headquartered in Paris, France, and Cambridge, Massachusetts, the company’s ordinary shares are listed on Euronext Growth.
At SEQENS, we have ambitious goals to provide our customers with the very best of what we do: active ingredients, pharmaceutical intermediates, specialty ingredients, and more. With 10 R&D centers around the globe and 3,400 highly skilled, dedicated employees, we are steadily evolving and innovating across the entire value chain, from raw materials to active ingredients.
Our quality-focused culture and commitment to sustainability set us apart, ensuring that each product we develop or industrialize meets the highest standards. Our people go the extra mile to bring out the best in our products, and that’s why our customers trust us to bring the highest level of service and quality.